^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CCX559

i
Other names: CCX559
Company:
Amgen
Drug class:
PD-L1 inhibitor
Related drugs:
1year
Trial termination
|
CCX559
over1year
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity. (PubMed, PLoS One)
In a cynomolgus monkey pharmacodynamic study, CCX559 increased plasma levels of soluble PD-L1. These results support the clinical development of CCX559 for solid tumors; CCX559 is currently in a Phase 1, first in patient, multicenter, open-label, dose-escalation study (ACTRN12621001342808).
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD80 (CD80 Molecule)
|
PD-L1 expression
|
CCX559
over3years
[VIRTUAL] CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity (AACR 2021)
Using structural information and focused medicinal chemistry, we identified CCX559 as a potent inhibitor of PD-L1 interaction with PD-1. CCX559 prevented PD-L1/PD-1 inhibition of TCR signaling in a cell-based reporter assay, increased IFNγ secretion in allogeneic MLR assays, and increased tumor cell killing by human PBMCs. We demonstrated that CCX559 potentially employs multiple mechanisms to inhibit PD-L1, which are distinct from those published for human anti-PD-L1 antibodies.
PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma)
|
CCX559